{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:42:52Z","timestamp":1793058172820,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"crossref","award":["MAYFLOWERS"],"award-info":[{"award-number":["MAYFLOWERS"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2022,6,6]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Therapeutic advances have markedly increased life expectancy for those with cystic fibrosis (CF), resulting in a median predicted survival over 50 years. Consequently, people with CF (pwCF) are living through their reproductive years and the rate of pregnancy is rapidly rising. Despite the increased relevance of this topic, multicentre studies investigating the association between maternal health and choices made during pregnancy on maternal and fetal outcomes do not exist. Furthermore, there are very limited data on the outcomes following CF transmembrane conductance regulator (CFTR) modulator use during pregnancy and lactation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Ma<\/jats:italic>\n                      ternal and\n                      <jats:italic>F<\/jats:italic>\n                      eta\n                      <jats:italic>l O<\/jats:italic>\n                      utcomes in the\n                      <jats:italic>E<\/jats:italic>\n                      ra of Modulato\n                      <jats:italic>rs<\/jats:italic>\n                      (MAYFLOWERS) is a prospective, multicentre observational clinical trial which will enrol approximately 285 pregnant pwCF including those who are modulator ineligible and those who choose to continue or discontinue CFTR modulator therapy during pregnancy and lactation. The primary aim of this 35-month study is to assess whether lung function changes during pregnancy differ based on the continued use of modulators or other factors such as pre-existing comorbid conditions. Secondary objectives include evaluation of pregnancy related and obstetrical complications and changes in mental health.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The design of this study required special consideration of study burden on pregnant and lactating people with chronic illness in the setting of a substantial number of unanswered questions under these conditions. MAYFLOWERS is the first prospective clinical trial examining pregnancy in CF; the outcomes will guide providers on pregnancy management in pwCF and others with chronic respiratory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001289","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:00:46Z","timestamp":1655377246000},"page":"e001289","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design"],"prefix":"10.1136","volume":"9","author":[{"given":"Raksha","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Magaret","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Hospital, Seattle, Washington, USA"},{"name":"Department of Biostatistics, University of Washington, Seattle, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong T","family":"Vu","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Hospital, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M","family":"VanDalfsen","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Hospital, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Wilson","sequence":"additional","affiliation":[{"name":"Clinical Research Services, National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S","family":"Putman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Endocrinology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Hospital, Seattle, Washington, USA"},{"name":"Department of Biostatistics, University of Washington, Seattle, Texas, USA"},{"name":"Department of Pediatrics, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R","family":"Esther","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Taylor-Cousar","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"2025083112225558000_9.1.e001289.1","unstructured":"United States Cystic Fibrosis Foundation Patient Registry . Annual data report Bethesda, Maryland, 2020. Available: https:\/\/www.cfsmartreports.com\/resourcefiles\/2020%20Annual%20Data%20Report.pdf"},{"key":"2025083112225558000_9.1.e001289.2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12040"},{"key":"2025083112225558000_9.1.e001289.3","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X15575628"},{"key":"2025083112225558000_9.1.e001289.4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2013.08.004","article-title":"Cystic fibrosis and pregnancy in the modern era: a case control study","volume":"13","author":"Ahluwalia","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1471-0528.2002.01511.x","article-title":"Cystic fibrosis and pregnancy. Report from French data (1980-1999)","volume":"109","author":"Gillet","year":"2002","journal-title":"BJOG"},{"key":"2025083112225558000_9.1.e001289.6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/aogs.13185","article-title":"Pregnancy outcome in women with cystic fibrosis-related diabetes","volume":"96","author":"Reynaud","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2025083112225558000_9.1.e001289.7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rmed.2018.11.009","article-title":"A case-control study on pregnancy in Italian cystic fibrosis women. data from the Italian registry","volume":"145","author":"Giordani","year":"2018","journal-title":"Respir Med"},{"key":"2025083112225558000_9.1.e001289.8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcf.2020.09.002","article-title":"Baseline cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression","volume":"20","author":"Cohen-Cymberknoh","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1460"},{"key":"2025083112225558000_9.1.e001289.10","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201211-108OC"},{"key":"2025083112225558000_9.1.e001289.11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/14767058.2016.1161747","article-title":"Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis.","volume":"30","author":"Jelin","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025083112225558000_9.1.e001289.12","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.ajog.2014.07.018","article-title":"Medical and obstetric complications among pregnant women with cystic fibrosis","volume":"212","author":"Patel","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"2025083112225558000_9.1.e001289.13","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.16423","article-title":"The outcome of pregnancy in women with cystic fibrosis: a UK population based descriptive study","author":"Ashcroft","year":"2020","journal-title":"BJOG"},{"key":"2025083112225558000_9.1.e001289.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.02.006","article-title":"Parenthood impacts short-term health outcomes in people with cystic fibrosis","author":"Kazmerski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.8.672"},{"key":"2025083112225558000_9.1.e001289.16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10995-016-2181-z","article-title":"Attitudes and decision making related to pregnancy among young women with cystic fibrosis","volume":"21","author":"Kazmerski","year":"2017","journal-title":"Matern Child Health J"},{"key":"2025083112225558000_9.1.e001289.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2025083112225558000_9.1.e001289.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2025083112225558000_9.1.e001289.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2025083112225558000_9.1.e001289.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"2025083112225558000_9.1.e001289.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025083112225558000_9.1.e001289.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025083112225558000_9.1.e001289.23","unstructured":"Ivacaftor (Kalydeco), United States prescribing information, 2020. Available: https:\/\/pi.vrtx.com\/files\/uspi_ivacaftor.pdf"},{"key":"2025083112225558000_9.1.e001289.24","unstructured":"Lumacaftor\/ivacaftor (Orkambi) United States prescribing information, 2019 https:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf"},{"key":"2025083112225558000_9.1.e001289.25","unstructured":"Tezacaftor\/ivacaftor (Symdeko) United States prescribing information., 2020 https:\/\/pi.vrtx.com\/files\/uspi_tezacaftor_ivacaftor.pdf"},{"key":"2025083112225558000_9.1.e001289.26","unstructured":"(FDA) FDA . Pregnancy and lactation labeling rule. Available: https:\/\/www.fda.gov\/drugs\/labeling-information-drug-products\/pregnancy-and-lactation-labeling-drugs-final-rule"},{"key":"2025083112225558000_9.1.e001289.27","unstructured":"Elexacaftor\/tezacaftor\/ivacaftor (Trikafta) United States prescribing information, 2020. Available: https:\/\/pi.vrtx.com\/files\/uspi_elexacaftor_tezacaftor_ivacaftor.pdf"},{"key":"2025083112225558000_9.1.e001289.28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.31","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050418","article-title":"Fertility, pregnancy and lactation considerations for women with CF in the CFTR modulator era","volume":"11","author":"Jain","year":"2021","journal-title":"J Pers Med"},{"key":"2025083112225558000_9.1.e001289.32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.33","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and ivacaftor","author":"Collins","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.34","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202550"},{"key":"2025083112225558000_9.1.e001289.35","unstructured":"Cystic fibrosis Foundation community voice. Available: https:\/\/www.cff.org\/get-involved\/community-voice [Accessed 7 Feb 2022]."},{"key":"2025083112225558000_9.1.e001289.36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00065"},{"key":"2025083112225558000_9.1.e001289.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2015.08.003"},{"key":"2025083112225558000_9.1.e001289.38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (kiwi): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025083112225558000_9.1.e001289.40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30161-3"},{"key":"2025083112225558000_9.1.e001289.41","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.481"},{"key":"2025083112225558000_9.1.e001289.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6441.345"},{"key":"2025083112225558000_9.1.e001289.43","first-page":"193","article-title":"A class of diabetes in mother, glycemic control in early pregnancy and occurrence of congenital malformations in newborn infants","volume":"24","author":"Mironiuk","year":"1997","journal-title":"Clin Exp Obstet Gynecol"},{"key":"2025083112225558000_9.1.e001289.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460060063025"},{"key":"2025083112225558000_9.1.e001289.45","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401047"},{"key":"2025083112225558000_9.1.e001289.46","doi-asserted-by":"publisher","DOI":"10.1080\/j.0001-6349.2005.00606.x"},{"key":"2025083112225558000_9.1.e001289.47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-0029-1210327","article-title":"The effect of intensified conventional insulin therapy before and during pregnancy on the malformation rate in offspring of diabetic mothers","volume":"83","author":"Fuhrmann","year":"1984","journal-title":"Exp Clin Endocrinol"},{"key":"2025083112225558000_9.1.e001289.48","first-page":"292","article-title":"The prevention of diabetes-associated birth defects","volume":"12","author":"Reece","year":"1988","journal-title":"Semin Perinatol"},{"key":"2025083112225558000_9.1.e001289.49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/JPM.2006.062","article-title":"Outcome of fetuses in women with pregestational diabetes mellitus","volume":"34","author":"Galindo","year":"2006","journal-title":"J Perinat Med"},{"key":"2025083112225558000_9.1.e001289.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042973"},{"key":"2025083112225558000_9.1.e001289.51","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768"},{"key":"2025083112225558000_9.1.e001289.52","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S002"},{"key":"2025083112225558000_9.1.e001289.53","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-Srev"},{"key":"2025083112225558000_9.1.e001289.54","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1925"},{"key":"2025083112225558000_9.1.e001289.55","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1492"},{"key":"2025083112225558000_9.1.e001289.56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2025083112225558000_9.1.e001289.57","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1527932","article-title":"Glucose >200\u2009mg\/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes","volume":"2016","author":"Taylor-Cousar","year":"2016","journal-title":"J Diabetes Res"},{"key":"2025083112225558000_9.1.e001289.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32400-5"},{"key":"2025083112225558000_9.1.e001289.59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/a-0973-8565","article-title":"Successful pregnancy of a patient with cystic fibrosis genotype F508del\/ F508del and progressed pulmonary destruction on lumacaftor\/ivacaftor","volume":"231","author":"Mainz","year":"2019","journal-title":"Klin Padiatr"},{"key":"2025083112225558000_9.1.e001289.60","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13007"},{"key":"2025083112225558000_9.1.e001289.61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2025083112225558000_9.1.e001289.62","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000425668.87506.4c"},{"key":"2025083112225558000_9.1.e001289.63","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2005.7.253"},{"key":"2025083112225558000_9.1.e001289.64","doi-asserted-by":"publisher","DOI":"10.2337\/diab.19.9.644"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:23:07Z","timestamp":1756668187000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,6,16]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjresp-2022-001289"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001289","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}